Lupitidine Explained

Lupitidine (INN; lupitidine hydrochloride (USAN); development code SKF-93479) is a long-acting H₂ receptor antagonist^[1] developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed.^[2] It was shown to inhibit nocturnal gastric acid secretion^[3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.^[4]

Notes and References

1. Franzén L, Ghassemifar R, Malcherek P . Experimental mast cell activation improves connective tissue repair in the perforated rat mesentery . Agents and Actions . 33 . 3–4 . 371–7 . July 1991 . 1683107 . 10.1007/bf01986588 . 23827166 .
2. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014 . Springer . 978-1-4757-2085-3 . 745– .
3. Dammann HG, Müller P, Simon B . Inhibition of nocturnal acid secretion by H2-receptor-antagonist SKF 93479 . Lancet . 1 . 8265 . 224 . January 1982 . 6119582 . 10.1016/S0140-6736(82)90788-7 . 5525326 .
4. Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P . Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole . Toxicologic Pathology . 16 . 2 . 288–98 . 1 February 1988 . 2903544 . 10.1177/019262338801600222 . free .